Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
NCT01391273 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 173
Last updated 2019-07-08
Summary
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes.
Conditions
- Eyelash Hypotrichosis
Interventions
- DRUG
-
bimatoprost solution 0.03%
One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
- DRUG
-
bimatoprost vehicle solution
One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
Sponsors & Collaborators
-
Allergan
lead INDUSTRY
Principal Investigators
-
Medical Director · Allergan
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-01
- Primary Completion
- 2012-05-19
- Completion
- 2012-05-19
Countries
- Japan
Study Locations
More Related Trials
-
Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence
NCT00693420 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
NCT01448525 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
NCT06803654 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Safety of BT01001 Ophthalmic Solution
NCT07313722 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
NCT05579730 ·Status: COMPLETED ·Phase: PHASE3
-
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
NCT00560638 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
NCT05591755 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
NCT03565887 ·Status: COMPLETED ·Phase: PHASE3
-
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363700 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363713 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
NCT00893139 ·Status: COMPLETED ·Phase: PHASE2
-
Topical IL-1-Ra for Treatment of Posterior Blepharitis
NCT00681109 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability
NCT03063489 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
NCT07068958 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01240382 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
NCT01632137 ·Status: COMPLETED ·Phase: PHASE3
-
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
NCT00905762 ·Status: COMPLETED ·Phase: PHASE1
-
Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.
NCT03691636 ·Status: UNKNOWN ·Phase: NA
-
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
NCT01037179 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AG-80308 in Dry Eye Patients
NCT05372107 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Anterior Blepharitis With Microblepharoexfoliation Procedure
NCT04290455 ·Status: TERMINATED ·Phase: NA
-
0.01% Hypochlorous Acid in the Treatment of Blepharitis
NCT05608980 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT07264517 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
NCT04139122 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of EBI-005 in Dry Eye Disease (DED)
NCT02405039 ·Status: UNKNOWN ·Phase: PHASE3